What is MOKSHA8 PHARMACEUTICALS?
Founded in 2007 and headquartered in Berwyn, PA, MOKSHA8 PHARMACEUTICALS is a Latin American pharmaceutical company dedicated to commercializing high-quality medicines through best-in-class operations and stringent FCPA compliance. The company commenced its commercial operations in 2008, initially focusing on CNS products in Brazil and Mexico. MOKSHA8 PHARMACEUTICALS has established a broad alliance with Forest Laboratories across Latin America and maintains partnerships with industry leaders such as GSK, Sandoz, Aurobindo, and Accord in Brazil. The company was co-founded by Simba Gill and TPG Biotechnology, indicating a strong foundation in both scientific expertise and venture capital.
How much funding has MOKSHA8 PHARMACEUTICALS raised?
MOKSHA8 PHARMACEUTICALS has raised a total of $219.1M across 4 funding rounds:
Series A
$39M
Series B
$25.1M
Series C
$30M
Unspecified
$125M
Series A (2008): $39M with participation from TPG Biotech
Series B (2009): $25.1M led by Montreux Equity Partners
Series C (2010): $30M supported by Watson
Unspecified (2012): $125M featuring Forest Laboratories
Key Investors in MOKSHA8 PHARMACEUTICALS
Montreux Equity Partners
Montreux Equity Partners is likely a venture capital firm specializing in growth-stage investments, given its domain and participation in a Series B round.
Forest Laboratories
Forest Laboratories, a former pharmaceutical company known for licensing European drugs for the US market, was a strategic partner and investor in MOKSHA8 PHARMACEUTICALS, indicating a focus on pharmaceutical commercialization and market expansion.
TPG Biotech
TPG Biotech is a venture capital entity focused on the life sciences sector, providing strategic financial backing to companies like MOKSHA8 PHARMACEUTICALS.
What's next for MOKSHA8 PHARMACEUTICALS?
The recent major strategic investment suggests MOKSHA8 PHARMACEUTICALS is poised for significant expansion and potentially new market entries or product development. The company's established partnerships and operational history indicate a focus on scaling its commercialization efforts and solidifying its market presence. Future growth will likely involve leveraging its existing alliances and potentially forging new ones to enhance its product portfolio and geographic reach within the Latin American pharmaceutical landscape.
See full MOKSHA8 PHARMACEUTICALS company page
